Medscape7 小时
Promise for CAR T-Cell Therapies in Solid Tumors?
CAR T-cell therapies have demonstrated efficacy in treating blood cancers but, so far, their safety and effectiveness in ...
rheumatologyadvisor3 天
Gamma Delta CAR T-Cell Therapy Fast Tracked for SLE With Extrarenal Involvement
The FDA has granted Fast Track designation to ADI-001 for the treatment of refractory systemic lupus erythematosus with extrarenal involvement.
technologynetworks6 天
Study Finds No Evidence CAR T-Cell Therapy Causes Secondary Cancers
A study of 783 patients treated with CAR T cell therapy found no evidence that the therapy itself caused secondary cancers.
News Medical on MSN6 天
New study confirms CAR T cell therapy does not cause secondary cancers
Within a large group of more than 700 patients treated with CAR T cell therapy, researchers found no evidence that the therapy itself caused any type of secondary cancer in the modified T cells, ...
Gene modification can encourage T cell growth, improving cancer treatment's success rate
Researchers have identified a method to enhance the effectiveness of a promising cancer treatment. They found that modifying ...
BioSpace4 小时
BMS Positions Breyanzi for Another Indication as LOE Woes Mount
Adding a new indication for the CAR T cell therapy could help BMS offset the loss-of-exclusivity headwinds it faces in the ...
AFP2 小时
PHC and CCRM Collaborate to Develop Primary T-Cell Expansion Culture Processes to Enhance ...
PHC Corporation has signed a Master Collaboration Agreement with CCRM to work together on the development of primary ...
Upstate cancer survivor celebrates recovery with innovative CAR T-cell treatment
On this World Cancer Day, Chris Vogelsang, a cancer survivor from upstate New York, is celebrating his recovery thanks to a ...
The Pharma Letter2 天
BRIEF—Kite shares new data on CAR T cell therapy
Kite, a Gilead Sciences company, will share four posters that add to the growing body of evidence to support the clinical use of its chimeric antigen receptor (CAR) T-cell therapy portfolio, at the ...
Pharm Exec5 天
FDA Grants Fast Track Designation to Adicet Bio’s CAR T-cell Therapy for Systemic Lupus ...
The FDA has granted Fast Track Designation to Adicet Bio’s ADI-001, an allogeneic gamma delta CAR T-cell therapy, for ...
CARsgen's First Enrolled Subject in the THANK-u Plus™ Platform-Based Allogeneic CAR-T ...
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the ...